Speaker
Arrowhead Pharmaceuticals, Inc.
Date
1/18/22
Time
10:00 AM
Location
Virtual
Additional Information

Presenters:

Erich Altenhofer, Sr. Chemist, CMC Process Chemistry, Arrowhead Pharmaceuticals, Inc., Madison, WI.

Tania Mutchie, Sr. Scientist, Developmental Chemistry, Arrowhead Pharmaceuticals, Inc., Madison, WI.

Trevor Nykaza, Sr. Chemist, Developmental Chemistry, Arrowhead Pharmaceuticals, Inc., Madison, WI.

 

Join Zoom Meeting

https://arrowheadpharma.zoom.us/j/89923042988?pwd=TU8rUG1uRVhrYTFldUVja0VXZkhiZz09

Meeting ID: 899 2304 2988

Passcode: 624957

One tap mobile

+16699006833,,89923042988#,,,,*624957# US (San Jose)

+12532158782,,89923042988#,,,,*624957# US (Tacoma)

Dial by your location

+1 669 900 6833 US (San Jose)

+1 253 215 8782 US (Tacoma)

+1 346 248 7799 US (Houston)

+1 312 626 6799 US (Chicago)

+1 929 205 6099 US (New York)

+1 301 715 8592 US (Washington DC)

Meeting ID: 899 2304 2988

Passcode: 624957

Find your local number: https://arrowheadpharma.zoom.us/u/kbr4AVJ10d

Join by Skype for Business: https://arrowheadpharma.zoom.us/skype/89923042988

 

Arrowhead Pharmaceuticals, Inc. (Nasdaq: ARWR) is a clinical stage biopharmaceutical company that develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of our RNAi technologies enables us to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologics. Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver, lung, and solid tumors with a promising pipeline of preclinical candidates.

Arrowhead’s corporate headquarters, commercial, clinical and regulatory teams are in Pasadena, CA with research and development teams in Madison, WI and San Diego, CA. Our employees are nimble, science-driven innovators who are collaborating to bring new therapies to patients in need.